Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 29.8.2022 | EN | Official Journal of the European Union | C 326/28 |

---

Action brought on 12 July 2022 — Pascoe pharmazeutische Präparate v EUIPO — Novartis Pharma (PASCELMO)

(Case T-435/22)

(2022/C 326/38)

Language in which the application was lodged: English

Parties

Applicant: Pascoe pharmazeutische Präparate GmbH (Gießen, Germany) (represented by: M. Kinkeldey, S. Brandstätter and S. Clotten, lawyers)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: Novartis Pharma AG (Basel, Switzerland)

Details of the proceedings before EUIPO

Applicant of the trade mark at issue: Other party to the proceedings before the Board of Appeal

Trade mark at issue: International registration designating the European Union in respect of the word mark PASCELMO — International registration designating the European Union No 1 516 387

Procedure before EUIPO: Opposition proceedings

Contested decision: Decision of the Second Board of Appeal of EUIPO of 4 May 2022 in Case R 1890/2021-2

Form of order sought

The applicant claims that the Court should:

|  |  |
| --- | --- |
| — | annul the contested decision; |

|  |  |
| --- | --- |
| — | order that the costs of the proceedings be borne by the defendant and by the other party to the proceedings before the Board of Appeal if it joins as intervener. |

Pleas in law

|  |  |
| --- | --- |
| — | Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council; |

|  |  |
| --- | --- |
| — | Infringement of Article 94(1) of Regulation (EU) 2017/1001 of the European Parliament and of the Council. |

---

[Top](#document1)